Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) Income from Continuing Operations (2024 - 2025)

Kairos Pharma (KAPA) has disclosed Income from Continuing Operations for 2 consecutive years, with 1422000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Income from Continuing Operations fell 507.69% year-over-year to 1422000.0, compared with a TTM value of 5160000.0 through Jun 2025, changed N/A, and an annual FY2024 reading of 3013000.0, down 71.58% over the prior year.
  • Income from Continuing Operations was 1422000.0 for Q2 2025 at Kairos Pharma, down from 1262000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 234000.0 in Q2 2024 and bottomed at 1551000.0 in Q4 2024.